Literature DB >> 10952230

Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.

G Sölétormos1, P H Petersen, P Dombernowsky.   

Abstract

The variability of the tumor markers cancer antigen (CA) 15.3, carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) during steady state concentrations and the rate of increase during progression is described. One hundred and ninety-two patients were monitored during first-line chemotherapy for metastatic breast cancer and during follow-up. Blood specimens were sampled approximately every four weeks. Steady state concentrations were registered for 77 (CA 15.3), 96 (CEA), and 127 (TPA) patients with below cutoff level values and for 28 (CA 15.3), 25 (CEA), and 11 (TPA) patients with above cutoff level values. Clinical and marker progression was registered for 75 (CA 15.3), 62 (CEA), and 57 (TPA) patients. The coefficients of total variation of steady state concentrations (comprising the intra- and interassay analytical imprecision and the within subject biological variation) were higher below (14.9% CA 15.3, 15.4% CEA, 25.9% TPA) than above cutoffs (9.6% CA 15.3,6.0% CEA, 19.9% TPA). The variability was similar for CA 15.3 and CEA but higher for TPA. During progression the rates of increase in concentrations were similar for CA 15.3 (0.0257) and CEA (0.0214) and lower than for TPA (0.0346). Our data indicate that criteria for assessment of sequential tumor marker concentrations should consider the marker in question, the steady state variability, the cutoff value, and the rate of increase during disease progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952230     DOI: 10.1515/CCLM.2000.066

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

1.  Making the most of a patient's laboratory data: optimisation of signal-to-noise ratio.

Authors:  Per Hyltoft Petersen
Journal:  Clin Biochem Rev       Date:  2005-11

2.  Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.

Authors:  Yanan Kong; Junye Wang; Wanli Liu; Qiaolun Chen; Juan Yang; Weidong Wei; Mingqing Wu; Lu Yang; Xinhua Xie; Ning Lv; Jiaoli Guo; Laisheng Li; Jie Gao; Xiaoming Xie; Shuqin Dai
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.